Biocad signed the cooperation agreement with Sechenov University.
Coming back to the SPIEF’17, our colleagues from Sechenov University…
SPIEF and antibiotics resistance.
SPIEF passed last week in Saint-Petersburg. There was an interesting…
Pricy, unique and urgently needed for approval: a risky combo?
In 2016 EMA annual report, that recently was in the spotlight…
EMA: industry support increases steadily
Every decent regulatory agency urges to assure pharma industry…
Keytruda – a new hope for oncology.
Last week FDA has approved Keytruda (pembrolizumab) a special…
Drug is finally approved? It’s not over yet.
Successful approval does not always guarantee unconditional and…